InCell Art and Sanofi expand r&d collaboration

InCell Art, a French biotechnology company involved in macromolecular drug delivery systems has expanded its research agreement with Sanofi Pasteur, in order to evaluate its nanocarrier technologies in Sanofi Pasteur's vaccines.

-

InCell Art, a French biotechnology company involved in macromolecular drug delivery systems has expanded its research agreement with Sanofi Pasteur, in order to evaluate its nanocarrier technologies in Sanofi Pasteur's vaccines.

InCell Art says the ICA614 nanocarrier - a DNA synthetic formulation - features "unique, efficient and industrial characteristics", including an enhancement of the immunogenicity of plasmid DNA-encoding tumour or pathogen-derived antigens, a plasmid DNA dose reduction and an excellent safety profile.

The ICA614 is currently being tested by major players in vaccine development. It is said to be an important step towards the emergence of DNA vaccines. In Cell Art has also demonstrated that it can increase the immunogenicity of subunit vaccines with recombinant proteins.

In the absence of a recombinant antigen, ICANtibodies allows, from an in silico DNA antigenic sequence, the production of the most ambitious antibodies against any chosen antigen. ICANtibodies uses a multivalent immunisation protocol for high throughput antibody screening, which rapidly identifies antibodies of therapeutic or diagnostic interest.

The company is also pursuing promising approaches in DNA-based therapeutic and prophylactic vaccines with successful studies in animal models of cancers and infectious diseases.

In Cell Art also works closely with companies developing RNAi therapeutic products for interference with the expression of targeted disease-associated genes.

In addition, the company is commercialising ICAFectin441 and ICAFectin442, which are DNA and siRNA transfection reagents for primary and stem cells.

Companies